STOCK TITAN

Progyny, Inc. - PGNY STOCK NEWS

Welcome to our dedicated page for Progyny news (Ticker: PGNY), a resource for investors and traders seeking the latest updates and insights on Progyny stock.

Progyny, Inc. (Nasdaq: PGNY) is a leading fertility and family building benefits company that integrates service, science, technology, and data to provide comprehensive fertility solutions for self-insured employers. The company's unique approach offers members tailored, value-based treatment plans, leveraging the latest medical advancements to improve outcomes, shorten the time to pregnancy, and reduce fertility-related costs.

Progyny's benefit plans encompass a wide range of fertility solutions, including IVF (In Vitro Fertilization), IUI (Intrauterine Insemination), embryo banking, egg freezing, adoption, and surrogacy. These plans are supported by Progyny's network of high-quality fertility specialists, known for their expertise in performing Smart Cycle treatments.

Headquartered in New York City, Progyny has established itself as a transformative leader in the fertility benefits space, partnering with employers across various industries. The company's clients benefit from a premier network of fertility and women's health specialists, advanced clinical outcomes, and reduced healthcare costs.

Progyny has been recognized for its leadership and growth, earning accolades from CNBC Disruptor 50, Modern Healthcare’s Best Places to Work in Healthcare, Forbes’ Best Employers, Financial Times, Inc. 5000, Inc. Power Partners, and Crain’s Fast 50 for NYC.

In the third quarter of 2023, Progyny reported having 392 clients, a significant increase from 282 clients in the same period in 2022. The company's financial performance includes positive Adjusted EBITDA, demonstrating robust profitability and financial health. Progyny continues to expand its services and partnerships, ensuring comprehensive support for patients and employers alike.

For more information, visit www.progyny.com. Investors can reach out to James Hart at investors@progyny.com, and media inquiries can be directed to Selena Yang at media@progyny.com.

Rhea-AI Summary

Progyny (Nasdaq: PGNY), a leader in fertility benefits management, announced its executives will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 11:40 A.M. ET. The event will provide insights into their comprehensive fertility solutions aimed at improving patient care and reducing costs for employers. A live audiocast and replay will be available on Progyny's website. The company is noted for its innovative approach and recognition from various organizations, indicating its growth and leadership in the industry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.87%
Tags
conferences
-
Rhea-AI Summary

Progyny, Inc. (Nasdaq: PGNY) will release its financial results for Q1 2022 on May 5, 2022, after market close. A conference call will follow at 4:45 PM Eastern Time. Interested parties can join via phone or through a live webcast available on the company’s investor relations page. Progyny specializes in fertility benefits management, offering comprehensive solutions that enhance patient care while reducing employer healthcare costs. The company has gained recognition for its innovative approach and commitment to improving fertility solutions across the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.07%
Tags
none
-
Rhea-AI Summary

Progyny, Inc. (PGNY) and RESOLVE: The National Infertility Association are set to highlight National Infertility Awareness Week 2022 by ringing the Nasdaq Opening Bell on April 26, 2022, and lighting the Empire State Building in orange on April 27, 2022. This initiative aims to raise awareness about infertility, affecting 1 in 8 couples in the U.S. CEO Pete Anevski emphasized Progyny's mission to support over 100,000 individuals in their family building journeys. The event seeks to eliminate stigmas associated with infertility and calls on employers and legislators to address the crisis.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.97%
Tags
none
Rhea-AI Summary

Progyny (Nasdaq: PGNY), a top benefits management company in fertility and family building solutions, announced that CEO Pete Anevski and CFO Mark Livingston will engage in a fireside chat at the Barclays Global Healthcare Conference on March 15, 2022, at 3:50 P.M. ET. This event aims to discuss Progyny's innovative approach to fertility benefits, highlighting its comprehensive solutions that benefit employers, patients, and physicians. A live audiocast and replay will be accessible on their official website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
conferences
-
Rhea-AI Summary

Progyny, Inc. (PGNY) reported record revenues of $500.6 million for 2021, marking a 45% growth year-over-year. The fourth quarter revenue reached $127.6 million, up 27%, driven by a significant increase in clients. Despite the impact of the COVID-19 Omicron variant, the company maintained a high retention rate and successful sales season. However, net income in Q4 decreased to $15.1 million from $39.1 million the previous year, primarily due to a lower tax benefit. Looking ahead, 2022 guidance forecasts revenue of $730 million to $775 million, reflecting 46% to 55% growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.53%
Tags
none
-
Rhea-AI Summary

Progyny, Inc. (Nasdaq: PGNY) will announce its financial results for the quarterly period and full year ending December 31, 2021, on February 28, 2022. A conference call will be held at 4:45 PM ET to discuss the results, with access details provided for U.S. and international participants. An audio replay will be available until March 7, 2022. Progyny specializes in fertility and family building benefits, focusing on education and access to specialists while reducing costs for employers. The company has received recognition for its growth and leadership in the sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
none
Rhea-AI Summary

Progyny, Inc. (Nasdaq: PGNY), a leader in fertility benefits management, announced its CEO, Pete Anevski, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 8:15 A.M. ET. The presentation will be followed by a breakout session featuring President Michael Sturmer and CFO Mark Livingston. A live audiocast and replay will be accessible on Progyny's website. Progyny is recognized for its innovative fertility solutions that benefit patients, employers, and healthcare providers alike.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.18%
Tags
conferences
-
Rhea-AI Summary

Progyny (PGNY) reported a strong third quarter of 2021, with revenues of $122.3 million, marking a 24% increase year-over-year. The company added over 85 new clients, resulting in approximately 1.2 million new covered lives. Gross profit rose to $28.5 million with a gross margin of 23.3%, up from 21.1% in the previous year. Net income reached $16.8 million, a significant increase from $4.8 million last year. For 2022, Progyny anticipates revenue growth of about 50%, driven by new client launches.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.3%
Tags
none
-
Rhea-AI Summary

Progyny, Inc. (Nasdaq: PGNY) is set to release its financial results for the quarter ending September 30, 2021, on November 4, 2021, after market close. A conference call will follow at 4:45 PM ET, during which the company will discuss its results. Participants can join by dialing the provided numbers. An audio replay will be available until November 11, 2021. Progyny specializes in fertility and family-building benefits, focusing on comprehensive solutions that benefit employers, patients, and healthcare providers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.78%
Tags
none
Rhea-AI Summary

Progyny, a leader in fertility benefits management, announced that CEO David Schlanger and CFO Mark Livingston will participate in a fireside chat at the BofA Global Healthcare Conference on September 15, 2021, at 10:55 A.M. ET. The event will be accessible via a live audiocast on Progyny’s website. Progyny aims to redefine fertility and family building benefits, enhancing access to comprehensive care and reducing healthcare costs for employers. The company has received multiple recognitions for its growth and leadership.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.17%
Tags
conferences

FAQ

What is the current stock price of Progyny (PGNY)?

The current stock price of Progyny (PGNY) is $14.34 as of December 20, 2024.

What is the market cap of Progyny (PGNY)?

The market cap of Progyny (PGNY) is approximately 1.2B.

What services does Progyny offer?

Progyny offers a range of fertility solutions, including IVF, IUI, embryo banking, egg freezing, adoption, and surrogacy, supported by a network of high-quality fertility specialists.

Who are Progyny's clients?

Progyny's clients are self-insured employers across various industries who seek comprehensive fertility and family-building benefits for their employees.

How does Progyny's approach improve fertility outcomes?

Progyny's value-based treatment plans leverage the latest medical science and technology to improve outcomes, shorten the time to pregnancy, and reduce total fertility-related costs.

What recognition has Progyny received?

Progyny has been recognized by CNBC Disruptor 50, Modern Healthcare’s Best Places to Work in Healthcare, Forbes’ Best Employers, Financial Times, Inc. 5000, Inc. Power Partners, and Crain’s Fast 50 for NYC.

Where is Progyny headquartered?

Progyny is headquartered in New York City.

How many clients did Progyny have in the third quarter of 2023?

Progyny reported having 392 clients as of September 30, 2023.

What are the financial highlights of Progyny for the third quarter of 2023?

Progyny reported positive Adjusted EBITDA and an increase in the number of clients from 282 in the third quarter of 2022 to 392 in the same period in 2023.

How can investors and media contact Progyny?

Investors can contact James Hart at investors@progyny.com, and media inquiries can be directed to Selena Yang at media@progyny.com.

What is the Smart Cycle treatment?

Smart Cycle treatment is part of Progyny's fertility benefits solution, providing access to high-quality fertility specialists who perform advanced fertility treatments.

What makes Progyny's benefits solution unique?

Progyny's benefits solution integrates service, science, technology, and data to offer comprehensive, value-based fertility treatment plans, improving outcomes and reducing costs.

Progyny, Inc.

Nasdaq:PGNY

PGNY Rankings

PGNY Stock Data

1.21B
72.27M
6.97%
106.91%
13.41%
Health Information Services
Services-misc Health & Allied Services, Nec
Link
United States of America
NEW YORK